Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp

Cameron J. Holloway, Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W Rodway, Tom Ashmore, Denny Z H Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P W Grocott, Kieran Clarke

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.

Original languageEnglish (US)
Pages (from-to)459-467
Number of pages9
JournalHigh Altitude Medicine and Biology
Volume15
Issue number4
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

coenzyme Q10
Ubiquinone
Oxidative Phosphorylation
Autophagy
Energy Metabolism
Echocardiography
Adipose Tissue
Volunteers
Reactive Oxygen Species
Transcription Factors
Antioxidants
Phosphates
Research Personnel
Magnetic Resonance Imaging
Ions

Keywords

  • altitude
  • cardiac metabolism
  • Coenzyme Q10
  • heart function
  • hypoxia

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Public Health, Environmental and Occupational Health

Cite this

Holloway, C. J., Murray, A. J., Mitchell, K., Martin, D. S., Johnson, A. W., Cochlin, L. E., ... Clarke, K. (2014). Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp. High Altitude Medicine and Biology, 15(4), 459-467. https://doi.org/10.1089/ham.2013.1053

Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp. / Holloway, Cameron J.; Murray, Andrew J.; Mitchell, Kay; Martin, Daniel S.; Johnson, Andrew W.; Cochlin, Lowri E.; Codreanu, Ion; Dhillon, Sundeep; Rodway, George W; Ashmore, Tom; Levett, Denny Z H; Neubauer, Stefan; Montgomery, Hugh E.; Grocott, Michael P W; Clarke, Kieran.

In: High Altitude Medicine and Biology, Vol. 15, No. 4, 01.12.2014, p. 459-467.

Research output: Contribution to journalArticle

Holloway, CJ, Murray, AJ, Mitchell, K, Martin, DS, Johnson, AW, Cochlin, LE, Codreanu, I, Dhillon, S, Rodway, GW, Ashmore, T, Levett, DZH, Neubauer, S, Montgomery, HE, Grocott, MPW & Clarke, K 2014, 'Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp', High Altitude Medicine and Biology, vol. 15, no. 4, pp. 459-467. https://doi.org/10.1089/ham.2013.1053
Holloway, Cameron J. ; Murray, Andrew J. ; Mitchell, Kay ; Martin, Daniel S. ; Johnson, Andrew W. ; Cochlin, Lowri E. ; Codreanu, Ion ; Dhillon, Sundeep ; Rodway, George W ; Ashmore, Tom ; Levett, Denny Z H ; Neubauer, Stefan ; Montgomery, Hugh E. ; Grocott, Michael P W ; Clarke, Kieran. / Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp. In: High Altitude Medicine and Biology. 2014 ; Vol. 15, No. 4. pp. 459-467.
@article{966e5d261798438bb6eee66bdcb76b1e,
title = "Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp",
abstract = "Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11{\%} in controls (p<0.05) and by 16{\%} in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18{\%} in controls (p<0.05) and by 21{\%} in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.",
keywords = "altitude, cardiac metabolism, Coenzyme Q10, heart function, hypoxia",
author = "Holloway, {Cameron J.} and Murray, {Andrew J.} and Kay Mitchell and Martin, {Daniel S.} and Johnson, {Andrew W.} and Cochlin, {Lowri E.} and Ion Codreanu and Sundeep Dhillon and Rodway, {George W} and Tom Ashmore and Levett, {Denny Z H} and Stefan Neubauer and Montgomery, {Hugh E.} and Grocott, {Michael P W} and Kieran Clarke",
year = "2014",
month = "12",
day = "1",
doi = "10.1089/ham.2013.1053",
language = "English (US)",
volume = "15",
pages = "459--467",
journal = "High Altitude Medicine and Biology",
issn = "1527-0297",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Oral coenzyme Q10 supplementation does not prevent cardiac alterations during a high altitude trek to Everest base camp

AU - Holloway, Cameron J.

AU - Murray, Andrew J.

AU - Mitchell, Kay

AU - Martin, Daniel S.

AU - Johnson, Andrew W.

AU - Cochlin, Lowri E.

AU - Codreanu, Ion

AU - Dhillon, Sundeep

AU - Rodway, George W

AU - Ashmore, Tom

AU - Levett, Denny Z H

AU - Neubauer, Stefan

AU - Montgomery, Hugh E.

AU - Grocott, Michael P W

AU - Clarke, Kieran

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.

AB - Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000 - 000, 2014. - Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.

KW - altitude

KW - cardiac metabolism

KW - Coenzyme Q10

KW - heart function

KW - hypoxia

UR - http://www.scopus.com/inward/record.url?scp=84919694407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919694407&partnerID=8YFLogxK

U2 - 10.1089/ham.2013.1053

DO - 10.1089/ham.2013.1053

M3 - Article

C2 - 24661196

AN - SCOPUS:84919694407

VL - 15

SP - 459

EP - 467

JO - High Altitude Medicine and Biology

JF - High Altitude Medicine and Biology

SN - 1527-0297

IS - 4

ER -